Senile systemic amyloidosis presenting with heart failure: A comparison with light chain-associated amyloidosis

Archives of Internal Medicine

Volumn 165, Issue 12, 2005, Pages 1425-1429

  Ng, Belinda ^a   Connors, Lawreen H ^a   Davidoff, Ravin ^a   Skinner, Martha ^a   Falk, Rodney H ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD VANGUARD MEDICAL ASSOCIATES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PROTEIN; IMMUNOGLOBULIN LIGHT CHAIN;

AGE DISTRIBUTION; AGED; AMYLOIDOSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; COMPARATIVE STUDY; CONTRAST ECHOCARDIOGRAPHY; CONTROLLED STUDY; DISEASE SEVERITY; ELECTROCARDIOGRAPHY MONITORING; FEMALE; HEART AMYLOIDOSIS; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE WALL; HUMAN; LIGHT CHAIN; MALE; MEDICAL ASSESSMENT; PATIENT REFERRAL; PATIENT SELECTION; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZATION; SENILE AMYLOIDOSIS; SEX DIFFERENCE; ADULT; AGE; CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; ECHOGRAPHY; FOLLOW UP; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PHYSIOLOGY; SURVIVAL RATE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; AMYLOIDOSIS; CARDIOMYOPATHIES; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MALE; MIDDLE AGED; SURVIVAL RATE;

EID: 22144438713     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.165.12.1425     Document Type: Article

References (21)

1. Dubrey SW, Cha K, Anderson J, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM. 1998;91:141-157.
2. Hattori T, Takei Y, Koyama J, Nakazato M, Ikeda S. Clinical and pathological studies of cardiac amyloidosis in transthyretin type familial amyloid polyneuropathy. Amyloid. 2003;10:229-239.
3. Falk RH. The neglected entity of familial cardiac amyloidosis in African Americans. Ethn Dis. 2002;12:141-143.
4. Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid. 2003;10:160-184.
5. Dubrey SW, Cha K, Skinner M, LaValley M, Falk RH. Familial and primary (AL) cardiac amyloidosis. Heart. 1997;78:74-82.
6. Chung CM, Connors LH, Benson MD, Walsh MT. Biophysical analysis of normal transthyretin. Amyloid. 2001;8:75-83.
7. Cornwell GG, Murdoch WL, Kyle RA, Westermark P, Pitkanen P. Frequency and distribution of senile cardiovascular amyloid. Am J Med. 1983;75:618-623.
8. Pitkanen P, Westermark P, Cornwell GG III. Senile systemic amyloidosis. Am J Pathol. 1984;117:391-399.
9. Westermark P, Sletten K, Johansson B, Cornwell GG III. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci U S A. 1990;87:2843-2845.
10. Westermark P, Bergstrom J, Solomon A, Murphy C, Sletten K. Transthyretin-derived senile systemic amyloidosis. Amyloid. 2003;10(suppl 1):48-54.
11. Kyle RA, Spittell PC, Gertz MA, et al. The premortem recognition of systemic senile amyloidosis with cardiac involvement. Am J Med. 1996;101:395-400.
12. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med. 1997;337:898-909.
13. Connors LH, Ericsson T, Skare J, Jones LA, Lewis WD, Skinner M. A simple screening test for variant transthyretins associated with familial transthyretin amyloidosis using isoelectric focusing. Biochim Biophys Acta. 1998;1407:185-192.
14. Lim A, Prokaeva T, McComb ME, et al. Characterization of transthyretin variants in familial transthyretin amyloidosis by mass spectrometric peptide mapping and DNA sequence analysis. Anal Chem. 2002;74:741-751.
15. Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med. 2004;140:85-93.
16. Sanchorawala V, Wright DG, Seldin DC, et al. High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial. Bone Marrow Transplant. 2004;33:381-388.
17. Liao R, Jain M, Teller P, et al. Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation. 2001;104:1594-1597.
18. Brenner DA, Jain M, Pimentel DR, et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res. 2004;94:1008-1010.
19. Perlini S, Palladini G, Vezzoli M, et al. Reduction of circulating amyloidogenic light chains improves myocardial function and survival despite unaltered amount of amyloid myocardial deposits. Circulation. 2004;110(suppl 3):602.
20. Hammarstrom P, Wiseman RL, Powers ET, Kelly JW. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science. 2003;299:713-716.
21. Altland K, Winter P, Saraiva MJ, Suhr O. Sulfite and base for the treatment of familial amyloidotic polyneuropathy. Neurogenetics. 2004;5:61-67.